EXEL Exelixis Inc.

27.53
-0.77  -3%
Previous Close 28.30
Open 28.35
Price To book 53.98
Market Cap 8091196501
Shares 293,904,704
Volume 5,057,134
Short Ratio 4.75
Av. Daily Volume 3,919,269

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 171077393
  2. 8-K - Current report 171077357
  3. CT ORDER - Confidential treatment order 171028997
  4. CT ORDER - Confidential treatment order 171028042
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 3Q 2017.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 enrollment completed 1Q 2017.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 trial initiation announced July 10, 2017.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018.
Cabozantinib - CABOSUN
First-Line RCC - cancer
Phase 3 data released October 16, 2017 - primary endpoint met. sNDA filing due 1Q 2018.
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer

Latest News

  1. Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
  2. Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma
  3. Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
  4. Company News For Oct 17, 2017
  5. FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
  6. Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
  7. Why Exelixis' Rebound Is Just Getting Started
  8. Today's Research Reports on Stocks to Watch: Dynavax and Exelixis
  9. Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017
  10. What Happened in the Stock Market Today
  11. Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News
  12. Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip
  13. Wall Street High on Monday
  14. Why Exelixis, Inc. Rose Higher Today
  15. Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers
  16. Exelixis Cancer Treatment Hits Key Milestone
  17. Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug
  18. Exelixis cancer drug meets key goal in late-stage trial
  19. Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
  20. Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

SEC Filings

  1. 8-K/A [Amend] - Current report 171077393
  2. 8-K - Current report 171077357
  3. CT ORDER - Confidential treatment order 171028997
  4. CT ORDER - Confidential treatment order 171028042
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000075
  6. 8-K - Current report 171000017
  7. 8-K - Current report 17973376
  8. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17966023
  9. S-8 - Securities to be offered to employees in employee benefit plans 17870382
  10. 8-K - Current report 17870342